



#10 1729

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : APOLIPOPROTEIN BIOPOLYMER MARKER
INDICATIVE OF NORMAL HUMAN
SERIAL NUMBER : 09/993,300
FILING DATE : November 23, 2001
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1741
ATTORNEY DOCKET NO. : 2132.107

RECEIVED
MAR 28 2003
TC 1700

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 3-20-03

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

- X Supplemental Information Disclosure Statement
- X Certification Pursuant to 37 C.F.R. §1.97(e)
- X Copy of International Search Report
- X PTO-1449
- X References

RECEIVED
APR 02 2003
TECH CENTER 1600/2900

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

Date: 3-19-2003



#10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : APOLIPOPROTEIN BIOPOLYMER MARKER
INDICATIVE OF NORMAL HUMAN
SERIAL NUMBER : 09/993,300
FILING DATE : November 23, 2001
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1741
ATTORNEY DOCKET NO. : 2132.107

RECEIVED
MAR 28 2003
TC 1700

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 3-20-03

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 02 2003

TECH CENTER 1600/2900

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.

A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

Date: 3-19-2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : APOLIPOPROTEIN BIOPOLYMER MARKER
INDICATIVE OF NORMAL HUMAN
SERIAL NUMBER : 09/993,300
FILING DATE : November 23, 2001
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1741
ATTORNEY DOCKET NO. : 2132.107

RECEIVED
MAR 28 2003
TC 1700

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 3-20-03

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.


Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

Date: 3-19-2003

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

Form PTO-1449
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2132.107APPLICATION NO.
09/993,300**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
JACKOWSKI et al.FILING DATE
11/23/01GROUP
1741**U.S. PATENT DOCUMENTS**

| EXAMINER'S INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-----------------------|-----------------|-------|----------------|-------|----------|-------------------------------|
| | 6,033,862 | 03/00 | Matsuda et al. | | | |
| | | | | | | |
| | | | | | | |
| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
| | ✓ 0 770 875 | 05/97 | Europe | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

RECEIVED
MAR 28 2003
TC 1700

RECEIVED

APR 02 2003

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|---|---|
| ✓ | Jungblut, et al., "Proteomics in human disease: Cancer, heart and infectious diseases", Electrophoresis (1999) Vol. 20, No. 10, pp. 2100-2110. |
| ✓ | Kim, et al, "The reduction of NADH Ubiquinone oxidoreductase 24-and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease", Life Sciences (2001) Vo. 68, No. 24, pp. 2741-2750. |
| ✓ | Finan, et al., "The complete sequence of the 1,683-kb pSymB megaplasmid from the N ₂ -fixing and endosymbiont Sinorhizobium meliloti", Proceedings of the National Academy of Sciences of the United States (2001) Vol. 98, No. 17, pp. 9889-9894. |
| ✓ | Database Swissprot 'Online! Retrieved from EBI (2000) accession no. Q9N3X8; XP-002232170. |
| ✓ | Colwell, "Multifactorial Aspects of the Treatment of the Type II Diabetic Patient", Clinical and Experimental (1997), Vol. 46, No. 12, Supp 1, pp. 1-4. |

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.